IART
Integra LifeSciences Holdings
15.50$
-3.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 33.5% | 24.7% | 27.4% | 25.6% | 24.9% | 26.0% | 34.2% | 30.5% | 29.9% | 28.0% | 26.8% | 32.2% | |
| 4.6% | 2.7% | 5.6% | 5.4% | 4.5% | 6.0% | 13.0% | 13.6% | 11.7% | 7.3% | 6.1% | 6.5% | |
| 4.6% | 2.7% | 5.6% | 5.4% | 4.5% | 6.0% | 13.0% | 13.6% | 11.7% | 8.2% | 6.8% | 7.3% | |
| 8.4% | 7.5% | 8.2% | 7.8% | 8.6% | 8.3% | 6.2% | 6.4% | 6.8% | 6.9% | 6.7% | 7.7% | |
| 15.0% | 11.9% | 12.0% | 9.2% | 9.0% | 9.6% | 8.6% | 8.4% | 8.3% | 10.3% | 10.6% | 13.7% | |
| 13.3% | 11.6% | 12.3% | 8.4% | 9.7% | 10.2% | 8.0% | 8.2% | 8.0% | – | – | – | |
| 23.1% | 28.9% | 28.2% | 29.2% | 29.8% | 28.9% | 25.8% | 26.8% | 26.7% | 27.9% | 27.2% | 17.1% | |
| 29.1% | 34.0% | 31.0% | 36.1% | 34.7% | 31.2% | 27.4% | 30.3% | 29.0% | 28.2% | 29.9% | 31.5% | |
| 55.4% | 57.7% | 53.6% | 70.0% | 55.7% | 57.1% | 58.1% | 55.5% | 53.6% | 58.0% | 61.7% | 71.0% | |
| 8.0% | 7.8% | 6.8% | 10.9% | 8.4% | 10.0% | 11.1% | 9.0% | 8.3% | 8.1% | 22.8% | 12.7% | |
| 0.2% | 0.8% | 36.8% | 1.9% | 0.7% | 2.1% | 4.4% | 2.0% | 1.7% | 0.8% | 15.4% | 3.9% | |
| 2.2% | 2.0% | 1.6% | 2.9% | 2.4% | 3.4% | 1.5% | 1.6% | 2.6% | 2.4% | 2.0% | 2.7% | |
| 39.7% | 39.5% | 36.8% | 55.5% | 38.9% | 36.3% | 39.0% | 36.7% | 33.4% | 39.3% | 29.6% | 48.0% | |
| 44.6% | 42.3% | 46.4% | 30.0% | 44.3% | 42.9% | 41.9% | 44.5% | 46.4% | 42.0% | 38.3% | 29.0% | |
| 20.0% | 8.2% | 12.2% | 8.9% | 11.2% | 12.1% | 14.7% | 18.5% | 22.6% | 25.0% | 23.3% | 11.8% | |
| 4.2% | 4.2% | 4.4% | 2.5% | 2.7% | 2.6% | 2.4% | 2.3% | 2.1% | 2.1% | 1.9% | 2.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.